research Proposing Vascepa (Icosapent Ethyl) as Supplemental Treatment Targeting the Underlying Causes of Persistent, Post-Viral Symptoms Associated with COVID-19: A Case Series
Icosapent ethyl may help treat long-lasting symptoms after COVID-19.
Search
for
Sort by
Research
150-180 / 1000+ results 
research Host Genetic Susceptibility and Impacts of Dietary Factors on Covid-19
Certain genes and nutrients like vitamin D, zinc, and omega fatty acids affect COVID-19 severity and infection risk.
research Spironolactone: An Anti-androgenic and Anti-hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19
Spironolactone might help protect against severe lung problems in COVID-19 patients.
research Expression of concern: potential risk for developing severe COVID-19 disease among anabolic steroid users
Anabolic steroid users may face higher risk of severe COVID-19.
research Patients with bullous skin disease in a high‐epidemic COVID‐19 area, Bergamo, Italy
Oral mTOR inhibitors often cause skin and hair side effects but usually don't require stopping treatment.
research The impact of certain genetic variants (single nucleotide polymorphisms) on incidence and severity of COVID‐19
Certain genetic differences may affect how likely someone is to get COVID-19 and how severe it might be.
research Safety and efficacy of oral administrated cepharanthine in non-hospitalized, asymptomatic or mild COVID-19 patients: a Double-blind, randomized, placebo-controlled trial
Cepharanthine is safe but not effective in significantly reducing COVID-19 recovery time.
research Safety and Efficacy of Oral administrated Cepharanthine in Non-hospitalized, asymptomatic or mild COVID-19 patients: A Double-blind, Randomized, Placebo-controlled Trial
Cepharanthine is safe but not clearly effective in speeding up COVID-19 recovery.
research Androgen deprivation therapy and hormonal status in men with COVID-19
Hormonal status from androgen deprivation therapy may affect COVID-19 severity in men.
research Cepharanthine: a review of the antiviral potential of a Japanese-approved alopecia drug in COVID-19
Cepharanthine, a Japanese hair loss drug, shows promise as a COVID-19 treatment but needs more testing.
research Factors associated with anti-SARS-CoV-2 IgG antibody production in patients convalescing from COVID-19
Men, diabetes, and high inflammation levels lead to higher COVID-19 antibodies.
research Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies
Blocking the virus's entry into cells by targeting certain pathways could lead to early COVID-19 treatments.
research COVID-19 in Africa: an ovarian victory?
Africa's low COVID-19 rates may be linked to early measures and possibly higher estrogen levels in women.
research The role of autologous micrografts injection from the scalp tissue in the treatment of COVID‐19 associated telogen effluvium: Clinical and trichoscopic evaluation
Injecting scalp tissue micrografts is a safe and effective treatment for hair loss after COVID-19.
research A case of chronic kidney disease patient with rapid deterioration of renal function, hair loss, and spontaneous resolution of facial warts after COVID‐19 infection
A COVID-19 infected patient with chronic kidney disease experienced worsened kidney function, hair loss, and unexpected wart clearance.
research Self-Reported Hair Loss Following COVID-19: An Observational Study
Many people experienced hair loss after having COVID-19, with the worst cases in hospitalized patients, and some saw hair regrowth within six months.
research COVID-19: Pulmonary and Extra Pulmonary Manifestations
COVID-19 affects multiple body systems, not just the lungs.
research Greater susceptibility to telogen effluvium in the setting of severe COVID-19 infection: findings from a retrospective cohort study
Severe COVID-19 increases the risk of hair loss.
research Evaluation of the Relationship between Favipiravir Use Status and Telogen Effluvium in Patients Diagnosed with COVID-19
Using Favipiravir, a COVID-19 treatment drug, likely doesn't cause hair loss.
research Reply to early onset effluvium secondary to COVID-19 and body-hair effluvium
COVID-19 can cause different types of hair loss, which may last up to 100 days, and treatments are still being explored.
research Long-term COVID-19 complications: a multidisciplinary clinic follow-up approach
A team of different healthcare experts is good for treating long-term COVID-19 issues.
research Trichodynia and telogen effluvium in COVID-19 patients: Results of an international expert opinion survey on diagnosis and management
COVID-19 patients often experience hair loss and scalp pain, which may be related to the severity of their infection and treatment drugs.
research Epidemiological characteristics of the COVID-19 outbreak in a secondary hospital in Spain
Older males had higher death rates, and Latin Americans were more often in the ICU during the COVID-19 outbreak in a Spanish hospital.
research Case Report: Rowell Syndrome–Like Flare of Cutaneous Lupus Erythematosus Following COVID-19 Infection
COVID-19 may trigger severe skin flare-ups in people with autoimmune conditions like lupus.
research Global Impact of Coronavirus Disease 2019 (COVID-19)
COVID-19 has widely affected health, various industries, and the economy, but also led to more remote work and less pollution.
research After Math of COVID Through Eyes of Tricoscopy
COVID-19 can cause significant hair loss.
research Characteristics of hair loss in COVID-19 patients in Thailand.
COVID-19 patients in Thailand typically started losing hair about 30 days after infection, with women experiencing more severe hair loss.
research O papel dos andrógenos na alopecia androgenética associada à gravidade do COVID-19
Androgens play a key role in causing alopecia by changing the hair growth cycle.
research COVID-19 Can Exacerbate Pattern Hair Loss and Trigger Telogen Effluvium - The Role of Proteoglycan Replacement Therapy with Nourkrin® in Clinical Treatment of COVID-19 Associated Hair Loss
COVID-19 may worsen hair loss, and Nourkrin® could be a safe treatment option, but more research is needed.
research COVID-19 in adult patients with pre-existing chronic cardiac, respiratory and metabolic disease: a critical literature review with clinical recommendations
COVID-19 severely affects older adults with chronic heart, lung, or metabolic diseases.